Abstract 1435P
Background
Esophageal squamous cell carcinoma (ESCC) treatment remains challenging due to its high recurrence rates and discouraging survival outcomes. Astragalus Polysaccharides (PG2, PhytoHealth Corporation, Taiwan, ROC), as a drug therapy for cancer-related fatigue relief, has the ability to modulate macrophage polarization and synergistically anti-cancer effect. PG2 combined with neoadjuvant chemoradiotherapy might be a novel therapeutic strategy in patients with ESCC.
Methods
The prospective, multicenter, open-label, and randomized trial included patients with stage IIb to IIIb resectable locally advanced ESCC who would undergo concurrent chemoradiotherapy (CCRT) followed by surgery. Eligible patients were randomized to receive either CCRT combined with PG2 or CCRT alone. This study aimed to identify differences in survival, objective response rate (ORR), and major pathologic response (MPR) rate between two arms. The Immunomodulatory effects of PG2 were also explored.
Results
Thirty-eight ESCC patients were enrolled. CCRT combined with PG2 resulted in significantly superior overall survival (OS) compared to CCRT alone [HR 0.32; 95% CI, 0.1-0.96; P=0.042]. The ORR in CCRT-PG2 arm was 85.0%, higher than that in CCRT alone arm was 62.5%, and progressive disease made surgery unfeasible for 5% of cases in CCRT-PG2 arm, while 25.0% in CCRT alone arm. Primary tumor MPR rate was achieved by 100.0% in CCRT-PG2 Arm and 80.0% in CCRT alone arm, respectively. CCRT-PG2 arm exhibited a consistent and significant decline in blood regulatory T cell proportions, and the suppressions of the serum levels of proinflammatory cytokines (IL-12, IL-1b, and IL-6), immune- suppressive cytokines (IL-10 and IL-4), and angiogenic growth factors (VEGF and MCP-1) were also observed in CCRT-PG2 arm, with a significant difference compared to the CCRT alone arm. PG2 also conferred an immunomodulatory effect by reducing CCRT-induced polarization of tumor-associated macrophages from M1 to M2.
Conclusions
PG2 combined with preoperative CCRT in advanced esophageal cancer has shown promising improvements in OS and modulation of the immune microenvironment.
Clinical trial identification
NCT03611712 (PH-CP028/PH-CP028-1).
Editorial acknowledgement
Legal entity responsible for the study
MacKay Memorial Hospital, Tri-Service General Hospital, Far-Eastern Memorial Hospital, Taipei Medical University - Shuang-Ho Hospital, PhytoHealth Corporation.
Funding
PhytoHealth Corporation, Taiwan.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1456P - First in human phase I/II trial of claudin 18.2 ADC RC118 in patients with advanced gastric/gastroesophageal junction cancer
Presenter: Tianshu Liu
Session: Poster session 18
1457P - Tumor immune microenvironment subtypes of esophageal squamous cell carcinoma and their strong ability to predict the efficacy of neoadjuvant immunotherapy
Presenter: Guangyu Yao
Session: Poster session 18
1458P - Impact of 68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) on staging and treatment in patients with gastric cancer
Presenter: Shunyu Zhang
Session: Poster session 18
Resources:
Abstract
1459P - Long-term management and outcomes in gastroesophageal cancer in Norway
Presenter: Aleksander Kolstad
Session: Poster session 18
1460P - Association between effectiveness of treatment with curative intent and outcomes of first-line systemic therapy in metachronous metastatic esophagogastric cancer
Presenter: Denice Kamp
Session: Poster session 18
1462P - A pilot study of hypoxia as a potential resistance mechanism to PD-1 checkpoint blockade therapy in neoadjuvant treatment of esophageal squamous cell carcinoma (HYPERION)
Presenter: Bin Li
Session: Poster session 18
1463P - The presence of liver metastases is associated with systemic immune suppression in gastroesophageal cancer
Presenter: Sebastiaan Siegerink
Session: Poster session 18
1464P - Chemo-radiation alone associated with higher risk of death compared to chemo-radiation plus surgery in esophageal squamous cell carcinoma
Presenter: Brian Housman
Session: Poster session 18
1465P - Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy
Presenter: Takeru Wakatsuki
Session: Poster session 18